ACEI/ARBs를 복용 중인 환자들, 코로나-19(중국 바이러스), Patients receiving ACEI/ARBs, COVID-19(China virus)

 

Patients receiving ACE inhibitors/ARBs

 

 

Patients receiving angiotensin-converting enzyme (ACE) inhibitors or angiotensin receptor blockers (ARBs)should continue treatment with these agents.This approach is supported by multiple guideline panels.

 

There has been speculation that patients with COVID-19 who are receiving these agents may be at increased risk for adverse outcomes.Angiotensin-converting enzyme 2 (ACE2) is a receptor for SARS-CoV-2, and renin-angiotensin-aldosterone system inhibitors can increase ACE2 levels. Although patients with cardiovascular disease, hypertension, and diabetes may have a more severe clinical course in the setting of infection with SARS-CoV-2,there is no evidence to support an association with these agents. In addition, stopping these agents in some patients may exacerbate comorbid cardiovascular or kidney disease and lead to increased mortality.